<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404206</url>
  </required_header>
  <id_info>
    <org_study_id>19762</org_study_id>
    <secondary_id>2017-005049-67</secondary_id>
    <nct_id>NCT03404206</nct_id>
  </id_info>
  <brief_title>A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the duration of analgesic efficacy as determined by the time to rescue medication
      of a single oral dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen
      400 mg (2 x 200 mg tablets) and placebo over 24 hours in subjects experiencing moderate to
      severe post-impaction surgery dental pain.

      To compare the overall analgesic effect (SPID 0-24) of a single dose of naproxen sodium 440
      mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.

      To compare the overall relief from pain (TOTPAR 0-24) of a single dose of naproxen sodium 440
      mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">September 5, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first use of rescue medication</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>To compare the duration of analgesic efficacy of test products as determined by the time to rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPID (Summed Pain Intensity Difference)</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOTPAR (Total Pain Relief)</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Naproxen Sodium (Aleve, BAY117031)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3/7 subjects receive total dose of 440mg Naproxen sodium (220 mg Naproxen Sodium/ orally, 2 tablets), single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen (Advil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3/7 subjects receive total dose of 400mg Ibuprofen (200 mg Ibuprofen/ orally, 2 tablets), single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1/7 subjects receive placebo orally, 2 tablets, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium (Aleve, BAY117031)</intervention_name>
    <description>220 mg / orally, 2 tablets, single dose</description>
    <arm_group_label>Naproxen Sodium (Aleve, BAY117031)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen (Advil)</intervention_name>
    <description>200 mg / orally, 2 tablets, single dose</description>
    <arm_group_label>Ibuprofen (Advil)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally, 2 tablets, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, ambulatory, male or female volunteers 16-40 years of age;

          -  Body mass index 18.0 to 30.0 kg/m2 inclusive;

          -  Scheduled to undergo surgical removal of at least 2 mandibular partial or full bony
             impacted third molars. Up to two maxillary third molars may be removed regardless of
             impaction level. Supernumerary teeth present may also be removed at the discretion of
             the oral surgeon;

          -  Mandibular molars must demonstrate modified Demirjian root classification stage D, E,
             F, G or H;

        Exclusion Criteria:

          -  History of hypersensitivity to naproxen sodium, ibuprofen, NSAIDS, aspirin, similar
             pharmacological agents, local anesthetics, rescue medication or components of the
             investigational products;

          -  Evidence or history of clinically significant (in the judgment of the investigator)
             hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,
             psychiatric, neurologic diseases, or malignancies within the last 5 years;

          -  Relevant concomitant disease such as asthma (exercise induced asthma is permitted)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postsurgical pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

